randomized [resa]
DOUBLE BLIND [resa]
placebo-controlled [resa]
FACTORIAL [resa]
Design [acty]
Study [mnob]
To [qlco]
Evaluate [ftcn]
Lipid [lipd]
Altered [ftcn]
Efficacy [qlco]
Safety [hcpp]
Profile [lbpr]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Tablet [bodm]
Compared [acty]
ezetimibe [orch, phsu]
Simvastatin [orch, phsu]
Patients [podg]
Primary hypercholesterolaemia [dsyn]
Objective [inpr]
Purpose [ftcn]
Study [mnob]
To [qlco]
Evaluate [ftcn]
Efficacy [qlco]
Safety [hcpp]
Profile [lbpr]
ezetimibe-simvastatin combination [orch, phsu]
Tablet [bodm]
Relative [famg]
ezetimibe [orch, phsu]
Simvastatin [orch, phsu]
Patients [podg]
Primary hypercholesterolaemia [dsyn]
Methods [inpr]
This [euka]
randomized [resa]
DOUBLE BLIND [resa]
placebo-controlled [resa]
Factorial Study [resa]
Design [acty]
Washout Period [tmco]
SINGLE BLIND [resa]
placebo [topp]
RUN-IN [tmco]
Patients [podg]
Low Density Lipoprotein Cholesterol [bacs, strd]
mg dl [qnco]
Triglycerides [bacs, lipd]
Equal [qlco]
mg dl [qnco]
randomized [resa]
Daily [tmco]
Treatments [topp]
weeks [tmco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
mg% [qnco]
Simvastatin [orch, phsu]
mg% [qnco]
placebo [topp]
Primary [qlco]
Efficacy [qlco]
Analysis [lbpr]
Mean [qnco]
Percent [qnco]
Change [ftcn]
baseline [bodm]
Study [mnob]
End Point [qlco]
secondary [neop]
End Point [qlco]
included [ftcn]
Percent [qnco]
Change [ftcn]
Lipid [lipd]
variables [qlco]
C-reactive protein [aapp, imft]
Result [ftcn]
Patients [podg]
randomized [resa]
treatment [ftcn]
Women [popg]
Men [popg]
Mean [qnco]
Age [orga]
Range [qnco]
Pooled [cnce]
treatment [ftcn]
Group [idcn]
treatment [ftcn]
Group [idcn]
Well [qlco]
Balanced [ftcn]
baseline [bodm]
Demographics [idcn]
Pooled [cnce]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Associated [qlco]
reductions [npop]
Pooled [cnce]
Simvastatin [orch, phsu]
ezetimibe [orch, phsu]
Alone [qnco]
P NOS [aapp, imft]
depend [medd]
Dose [qnco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Associated [qlco]
reductions [npop]
Non [ftcn]
High Density Lipoprotein Cholesterol [bacs, lipd]
Triglycerides [bacs, lipd]
High Density Lipoprotein Cholesterol [bacs, lipd]
Increased [qnco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Associated [qlco]
reductions [npop]
C-reactive protein [aapp, imft]
remnant-like particle cholesterol [aapp, lipd]
Simvastatin [orch, phsu]
Alone [qnco]
P NOS [aapp, imft]
More [ftcn]
Patients [podg]
Receive [qlco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Simvastatin [orch, phsu]
Concentrations [menp]
mg dl [qnco]
P NOS [aapp, imft]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Well [qlco]
Safety [hcpp]
Profile [lbpr]
Similar [qlco]
Simvastatin [orch, phsu]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Simvastatin [orch, phsu]
Incidence [qnco]
Consecutive [qlco]
Liver [bpoc]
Transaminase [aapp, enzy]
Levels [qlco]
Equal [qlco]
times [tmco]
Upper Limit of Normal [qnco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Simvastatin [orch, phsu]
P NOS [aapp, imft]
creatine kinase levels [fndg]
Equal [qlco]
times [tmco]
Upper Limit of Normal [qnco]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Simvastatin [orch, phsu]
P NOS [aapp, imft]
Conclusion [idcn]
EZETIMIBE/SIMVASTATIN [orch, phsu]
Tablet [bodm]
Highly [qlco]
effective [qlco]
Well [qlco]
lowering [spco]
therapy [ftcn]
Study [mnob]
Patients [podg]
Primary hypercholesterolaemia [dsyn]
[c] [qnco]
